Idebenone FDA Approval Status
FDA Approved: No
Generic name: idebenone
Company: Santhera Pharmaceuticals
Treatment for: Duchenne Muscular Dystrophy
Idebenone is a synthetic short-chain benzoquinone and a substrate for the enzyme NAD(P)H:quinone oxidoreductase (NQO1) in development for the treatment of Duchenne Muscular Dystrophy.
Development timeline for idebenone
| Date | Article |
|---|---|
| Jun 10, 2015 | Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
